Insider Buying: AgomAb Therapeutics (NASDAQ:AGMB) CEO Buys $50,880.00 in Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) CEO Tim Jasper Knotnerus bought 6,000 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were acquired at an average price of $8.48 per share, for a total transaction of $50,880.00. Following the completion of the transaction, the chief executive officer owned 16,823 shares in the company, valued at $142,659.04. This represents a 55.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Tim Jasper Knotnerus also recently made the following trade(s):

• On Tuesday, October 6th, Tim Jasper Knotnerus purchased 5,000 shares of AgomAb Therapeutics stock. The stock was acquired at an average cost of $8.70 per share, with a total value of $43,500.00.

AgomAb Therapeutics Stock Performance

Shares of AGMB opened at $9.08 on Friday. The company has a 50-day moving average price of $12.60 and a two-hundred day moving average price of $11.93. AgomAb Therapeutics NV has a 12 month low of $7.97 and a 12 month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Analysts expect that AgomAb Therapeutics NV will post -1.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AGMB has been the topic of several recent analyst reports. Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. B. Riley Financial assumed coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price for the company. HC Wainwright reiterated a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, September 16th. Piper Sandler initiated coverage on shares of AgomAb Therapeutics in a report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price objective on the stock. Finally, Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an “overweight” rating for the company. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.